Combined plerixafor and granulocyte colony‐stimulating factor for harvesting high‐dose hematopoietic stem cells: Possible niche for plerixafor use in pediatric patients. (16th March 2016)

• Record Type: Journal Article
• Authors: Bitan, Menachem; Eshel, Rinat; Sadot, Efraim; Friedman, Shirley; Pinhasov, Aviva; Levin, Dror; Dvir, Rina; Manisterski, Michal; Berger‐Achituv, Sivan; Rosenfeld‐Keidar, Hila; Elhasid, Ronit
• Is Part Of: Pediatric transplantation. Volume 20:Number 4(2016:Jun.)
• Page Start: 565
• Page End: 571
• Publication Date: 2016-03-16
• Subjects: autologous hematopoietic cell transplantation -- plerixafor -- harvesting -- neuroblastoma -- medulloblastoma; Transplantation of organs, tissues, etc. in children -- Periodicals; 617.95408305
• DOI: 10.1111/petr.12692
• Languages: English
• ISSNs: 1397-3142

Abstract

Abstract: PB is a source of HSC, especially for autologous HCT in solid tumors. However, there is a risk of failing to achieve the target number of SC after mobilization with growth factors alone in patients who were heavily pretreated with chemotherapy or those in need for tandem transplants. SC were harvested from seven pediatric patients with solid tumors who were in need of autologous HCT following combination GCSF and plerixafor. Six of them received plerixafor after failing to achieve enough SC with GCSF only, while the seventh patient received the combined protocol upfront. All seven patients achieved the target number of SC according to their treatment protocol. There were no adverse events. All patients underwent autologous HCT using the harvested HSC and achieved full engraftment. A protocol for harvesting autologous HCT using GCSF and plerixafor is feasible and safe in children with solid tumors who had been heavily pretreated with chemotherapy or needed tandem transplants.